fluorouracil has been researched along with Myocardial Ischemia in 33 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Myocardial Ischemia: A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fluorouracil (FU) is a cornerstone of colorectal cancer treatment; however, it has clinical and subclinical influence on the heart." | 9.14 | Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle. ( Hasbak, P; Jensen, SA; Mortensen, J; Sørensen, JB, 2010) |
| "The aim of this study was to evaluate the effects of a combination of folinic acid, 5-fluorouracil (5FU) and irinotecan (FOLFIRI 1) administered every 2 weeks in a population of elderly subjects with advanced colorectal cancer." | 9.13 | Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study. ( Badetti, JL; Berdah, JF; Chamorey, E; Codoul, JF; François, E; Hébert, C; Lesbats, G; Mari, V; Teissier, E, 2008) |
| "We examined the cardiotoxicity in 153 patients treated with capecitabine and oxaliplatin in two prospective trials for advanced colorectal cancer." | 8.82 | The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC). ( Cunningham, D; Ng, M; Norman, AR, 2005) |
| "In the present study, we aimed to evaluate temporal changes in heart-type fatty acid-binding protein (h-FABP) and myocardial performance index (Tei index) following administration of 5-fluorouracil (5-FU), a chemotherapeutic agent associated with myocardial ischemia induced by coronary vasospasm." | 7.85 | Usefulness of Heart-Type Fatty Acid-Binding Protein and Myocardial Performance Index for Early Detection of 5-Fluorouracil Cardiotoxicity. ( Agac, MT; Akdemir, R; Akyüz, AR; Aykan, AÇ; Boyacı, F; Celik, S; Cengiz, E; Erkan, H; Gökdeniz, T; Gül, İ; Kul, S; Turan, T, 2017) |
| "Myocardial ischemia induced by 5-fluorouracil (5-FU) is a relatively rare, but potentially serious, occurrence." | 7.70 | Failure of oral nitrate and calcium channel blocker therapy to prevent 5-fluorouracil-related myocardial ischemia: a case report. ( Akpek, G; Hartshorn, KL, 1999) |
| "An 85-year-old woman, with known stable angina pectoris, was prescribed 5-fluorouracil cream to treat a small basal cell carcinoma on the forehead." | 7.69 | Myocardial ischemia induced by topical use of 5-fluorouracil. ( Gotsman, MS; Gurewich, J; Rozenman, Y, 1995) |
| "A 40-year-old male patient with carcinoma of the tonsil was put on a 5-fluorouracil and cisplatinum regimen." | 7.68 | Myocardial ischemia after 5-fluorouracil chemotherapy. ( Ayyagari, S; Chag, M; Rastogi, N, 1993) |
| "Eight patients had ischemic heart disease." | 5.40 | Effort myocardial ischemia during chemotherapy with 5-fluorouracil: an underestimated risk. ( Buonadonna, A; Ejiofor, L; Lestuzzi, C; Lleshi, A; Meneguzzo, N; Scalone, S; Schmoll, HJ; Talamini, R; Tartuferi, L; Vaccher, E; Viel, E, 2014) |
| "5-Fluorouracil (5-FU) is a commonly employed chemotherapeutic agent." | 5.29 | In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. ( Chokshi, S; Fingert, HJ; Isner, JM; Mosseri, M; Varticovski, L, 1993) |
| "Fluorouracil (FU) is a cornerstone of colorectal cancer treatment; however, it has clinical and subclinical influence on the heart." | 5.14 | Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle. ( Hasbak, P; Jensen, SA; Mortensen, J; Sørensen, JB, 2010) |
| "The aim of this study was to evaluate the effects of a combination of folinic acid, 5-fluorouracil (5FU) and irinotecan (FOLFIRI 1) administered every 2 weeks in a population of elderly subjects with advanced colorectal cancer." | 5.13 | Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study. ( Badetti, JL; Berdah, JF; Chamorey, E; Codoul, JF; François, E; Hébert, C; Lesbats, G; Mari, V; Teissier, E, 2008) |
| "We examined the cardiotoxicity in 153 patients treated with capecitabine and oxaliplatin in two prospective trials for advanced colorectal cancer." | 4.82 | The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC). ( Cunningham, D; Ng, M; Norman, AR, 2005) |
| " Postulated mechanisms include direct myocardial ischemia, coronary spasm, or cardiotoxic impurities in fluorouracil formulation." | 4.79 | Fluorouracil cardiotoxicity. ( Anand, AJ, 1994) |
| "In the present study, we aimed to evaluate temporal changes in heart-type fatty acid-binding protein (h-FABP) and myocardial performance index (Tei index) following administration of 5-fluorouracil (5-FU), a chemotherapeutic agent associated with myocardial ischemia induced by coronary vasospasm." | 3.85 | Usefulness of Heart-Type Fatty Acid-Binding Protein and Myocardial Performance Index for Early Detection of 5-Fluorouracil Cardiotoxicity. ( Agac, MT; Akdemir, R; Akyüz, AR; Aykan, AÇ; Boyacı, F; Celik, S; Cengiz, E; Erkan, H; Gökdeniz, T; Gül, İ; Kul, S; Turan, T, 2017) |
| " Two of the patients could not be treated with 5-FU any more because they had developed a myocardial ischemia, which was most likely caused by fluorouracil." | 3.78 | 5-FU-induced cardiac toxicity--an underestimated problem in radiooncology? ( Hautmann, MG; Kölbl, O; Steger, F, 2012) |
| " This study was performed to evaluate the efficacy and safety of Endostar plus leucovorin calcium/ 5-fluorouracil/oxaliplatin (FOLFOX4) in treating patients with advanced colorectal cancer." | 3.77 | Clinical observation of Endostar® combined with chemotherapy in advanced colorectal cancer patients. ( Huang, XE; Li, CG; Li, Y; Qian, ZY; Xu, HX; Xu, X, 2011) |
| "Myocardial ischemia induced by 5-fluorouracil (5-FU) is a relatively rare, but potentially serious, occurrence." | 3.70 | Failure of oral nitrate and calcium channel blocker therapy to prevent 5-fluorouracil-related myocardial ischemia: a case report. ( Akpek, G; Hartshorn, KL, 1999) |
| "An 85-year-old woman, with known stable angina pectoris, was prescribed 5-fluorouracil cream to treat a small basal cell carcinoma on the forehead." | 3.69 | Myocardial ischemia induced by topical use of 5-fluorouracil. ( Gotsman, MS; Gurewich, J; Rozenman, Y, 1995) |
| "A 40-year-old male patient with carcinoma of the tonsil was put on a 5-fluorouracil and cisplatinum regimen." | 3.68 | Myocardial ischemia after 5-fluorouracil chemotherapy. ( Ayyagari, S; Chag, M; Rastogi, N, 1993) |
| "Many types of cancer are now curable or, if not cured, becoming a chronic illness." | 2.49 | Cancer survivorship: cardiotoxic therapy in the adult cancer patient; cardiac outcomes with recommendations for patient management. ( Carver, JR; Liu, J; Manrique, C; Steingart, RM; Yadav, N, 2013) |
| "Capecitabine is an oral prodrug of 5-fluorouracil (5-FU) which is converted in tumor cells to 5-FU by the enzyme thymidine phosphorylase." | 2.48 | Capecitabine induced cardiotoxicity: a case report and review of literature. ( Hashmi, A; Shoaib, M; Tunio, MA, 2012) |
| "Eight patients had ischemic heart disease." | 1.40 | Effort myocardial ischemia during chemotherapy with 5-fluorouracil: an underestimated risk. ( Buonadonna, A; Ejiofor, L; Lestuzzi, C; Lleshi, A; Meneguzzo, N; Scalone, S; Schmoll, HJ; Talamini, R; Tartuferi, L; Vaccher, E; Viel, E, 2014) |
| " In the man, the capecitabine dosage was reduced and metoprolol was prescribed, while in the woman the capecitabine was stopped." | 1.34 | [Myocardial ischaemia as a result of treatment with capecitabine]. ( Liem, AH; Planting, AS; van Halteren, HK, 2007) |
| "Cardiotoxicity is a rare but serious side effect of 5-flourouracil (5-FU)." | 1.31 | Cardiotoxicity of 5-flourouracil: two case reports. ( Ayanoğlu, E; Caymaz, O; Duman, D; Inanli, S; Tutkun, A, 2001) |
| "5-Fluorouracil (5-FU) is a commonly employed chemotherapeutic agent." | 1.29 | In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. ( Chokshi, S; Fingert, HJ; Isner, JM; Mosseri, M; Varticovski, L, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (24.24) | 18.2507 |
| 2000's | 13 (39.39) | 29.6817 |
| 2010's | 10 (30.30) | 24.3611 |
| 2020's | 2 (6.06) | 2.80 |
| Authors | Studies |
|---|---|
| Dyhl-Polk, A | 2 |
| Vaage-Nilsen, M | 2 |
| Schou, M | 2 |
| Vistisen, KK | 2 |
| Lund, CM | 1 |
| Kümler, T | 1 |
| Appel, JM | 1 |
| Nielsen, DL | 2 |
| Sillesen, AS | 1 |
| Serup-Hansen, E | 1 |
| Faber, J | 1 |
| Klausen, TW | 1 |
| Bojesen, SE | 1 |
| Hayashi, Y | 1 |
| Iijima, H | 1 |
| Isohashi, F | 1 |
| Tsujii, Y | 1 |
| Fujinaga, T | 1 |
| Nagai, K | 1 |
| Yoshii, S | 1 |
| Sakatani, A | 1 |
| Hiyama, S | 1 |
| Shinzaki, S | 1 |
| Makino, T | 1 |
| Yamasaki, M | 1 |
| Ogawa, K | 1 |
| Doki, Y | 1 |
| Takehara, T | 1 |
| Steingart, RM | 1 |
| Yadav, N | 1 |
| Manrique, C | 1 |
| Carver, JR | 1 |
| Liu, J | 1 |
| Lestuzzi, C | 3 |
| Vaccher, E | 2 |
| Talamini, R | 1 |
| Lleshi, A | 1 |
| Meneguzzo, N | 3 |
| Viel, E | 3 |
| Scalone, S | 1 |
| Tartuferi, L | 2 |
| Buonadonna, A | 1 |
| Ejiofor, L | 1 |
| Schmoll, HJ | 1 |
| Turan, T | 1 |
| Agac, MT | 1 |
| Aykan, AÇ | 1 |
| Kul, S | 1 |
| Akyüz, AR | 1 |
| Gökdeniz, T | 1 |
| Gül, İ | 1 |
| Cengiz, E | 1 |
| Boyacı, F | 1 |
| Erkan, H | 1 |
| Akdemir, R | 1 |
| Celik, S | 1 |
| Boekel, NB | 1 |
| Schaapveld, M | 1 |
| Gietema, JA | 1 |
| Russell, NS | 1 |
| Poortmans, P | 1 |
| Theuws, JC | 1 |
| Schinagl, DA | 1 |
| Rietveld, DH | 1 |
| Versteegh, MI | 1 |
| Visser, O | 1 |
| Rutgers, EJ | 1 |
| Aleman, BM | 1 |
| van Leeuwen, FE | 1 |
| Spasojević, I | 1 |
| Jelić, S | 1 |
| Zakrzewska, J | 1 |
| Bacić, G | 1 |
| Le Brun-Ly, V | 1 |
| Martin, J | 1 |
| Venat-Bouvet, L | 1 |
| Darodes, N | 1 |
| Labourey, JL | 1 |
| Genet, D | 1 |
| Tubiana-Mathieu, N | 1 |
| Jensen, SA | 2 |
| Hasbak, P | 1 |
| Mortensen, J | 1 |
| Sørensen, JB | 2 |
| Tunio, MA | 1 |
| Hashmi, A | 1 |
| Shoaib, M | 1 |
| Xu, HX | 1 |
| Huang, XE | 1 |
| Qian, ZY | 1 |
| Xu, X | 1 |
| Li, Y | 1 |
| Li, CG | 1 |
| Steger, F | 1 |
| Hautmann, MG | 1 |
| Kölbl, O | 1 |
| Görgülü, S | 1 |
| Oğuz, E | 1 |
| Zor, A | 1 |
| Zor, U | 1 |
| Gürdoğan, M | 1 |
| Tezel, T | 1 |
| Ng, M | 1 |
| Cunningham, D | 1 |
| Norman, AR | 1 |
| Rodríguez Roldán, JM | 1 |
| Lara Alvarez, MA | 1 |
| López Martínez, J | 1 |
| Díaz Abad, R | 1 |
| Caballero Campo, M | 1 |
| Del Nogal Sáez, F | 1 |
| Hrovatin, E | 1 |
| Zardo, F | 1 |
| Brieda, M | 1 |
| Dametto, E | 1 |
| Piazza, R | 1 |
| Antonini-Canterin, F | 1 |
| Nicolosi, GL | 1 |
| van Halteren, HK | 1 |
| Liem, AH | 1 |
| Planting, AS | 1 |
| van der Vliet, HJ | 1 |
| Kuenen, BC | 1 |
| François, E | 1 |
| Berdah, JF | 1 |
| Chamorey, E | 1 |
| Lesbats, G | 1 |
| Teissier, E | 1 |
| Codoul, JF | 1 |
| Badetti, JL | 1 |
| Hébert, C | 1 |
| Mari, V | 1 |
| Rozenman, Y | 1 |
| Gurewich, J | 1 |
| Gotsman, MS | 1 |
| McLachlan, SA | 1 |
| Millward, MJ | 1 |
| Toner, GC | 1 |
| Guiney, MJ | 1 |
| Bishop, JF | 1 |
| Rastogi, N | 1 |
| Chag, M | 1 |
| Ayyagari, S | 1 |
| Anand, AJ | 1 |
| Mosseri, M | 1 |
| Fingert, HJ | 1 |
| Varticovski, L | 1 |
| Chokshi, S | 1 |
| Isner, JM | 1 |
| Akpek, G | 1 |
| Hartshorn, KL | 1 |
| Nutting, C | 1 |
| Folkes, A | 1 |
| Tutkun, A | 1 |
| Inanli, S | 1 |
| Caymaz, O | 1 |
| Ayanoğlu, E | 1 |
| Duman, D | 1 |
| López Medrano, F | 1 |
| Sánchez Muñoz, A | 1 |
| Sánchez Sánchez, V | 1 |
| Costa Pérez-Herrero, JR | 1 |
| Heib, C | 1 |
| Schmidt, HJ | 1 |
| Heib, T | 1 |
| Lüer, B | 1 |
| Stasche, N | 1 |
| Picano, E | 1 |
| Bugnon, PY | 1 |
| Elhage, A | 1 |
| Bounoua, F | 1 |
| Gautier-Benoît, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Early Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer Patients Who Receiving Radical Concurrent Chemoradiotherapy and Immunotherapy: a Prospective, Randomized Controlled, Multicenter P[NCT04980716] | Phase 3 | 524 participants (Anticipated) | Interventional | 2021-06-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for fluorouracil and Myocardial Ischemia
| Article | Year |
|---|---|
Cancer survivorship: cardiotoxic therapy in the adult cancer patient; cardiac outcomes with recommendations for patient management.
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carboplatin; Cardiovascula | 2013 |
Capecitabine induced cardiotoxicity: a case report and review of literature.
Topics: Antimetabolites, Antineoplastic; Bradycardia; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Mal | 2012 |
The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinic | 2005 |
Fluorouracil cardiotoxicity.
Topics: Chest Pain; Electrocardiography; Electrocardiography, Ambulatory; Female; Fluorouracil; Heart; Human | 1994 |
2 trials available for fluorouracil and Myocardial Ischemia
| Article | Year |
|---|---|
Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2010 |
Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2008 |
27 other studies available for fluorouracil and Myocardial Ischemia
| Article | Year |
|---|---|
Incidence and risk markers of 5-fluorouracil and capecitabine cardiotoxicity in patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cardio | 2020 |
Myocardial Ischemia Induced by 5-Fluorouracil: A Prospective Electrocardiographic and Cardiac Biomarker Study.
Topics: Biomarkers; Electrocardiography; Fluorouracil; Humans; Myocardial Ischemia; Prospective Studies | 2021 |
The heart's exposure to radiation increases the risk of cardiac toxicity after chemoradiotherapy for superficial esophageal cancer: a retrospective cohort study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Cardiotoxicity; Chemoradi | 2019 |
Effort myocardial ischemia during chemotherapy with 5-fluorouracil: an underestimated risk.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Exercise Test; Female; Fluorouracil | 2014 |
Usefulness of Heart-Type Fatty Acid-Binding Protein and Myocardial Performance Index for Early Detection of 5-Fluorouracil Cardiotoxicity.
Topics: Aged; Biomarkers; Cardiotoxicity; Early Diagnosis; Echocardiography; Fatty Acid-Binding Proteins; Fe | 2017 |
Cardiovascular Disease Risk in a Large, Population-Based Cohort of Breast Cancer Survivors.
Topics: Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2016 |
Decreased oxygen transfer capacity of erythrocytes as a cause of 5-fluorouracil related ischemia.
Topics: Adult; Antimetabolites, Antineoplastic; Cisplatin; Electron Spin Resonance Spectroscopy; Erythrocyte | 2008 |
Cardiac toxicity with capecitabine, vinorelbine and trastuzumab therapy: case report and review of fluoropyrimidine-related cardiotoxicity.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothera | 2009 |
5-fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemothe | 2012 |
Clinical observation of Endostar® combined with chemotherapy in advanced colorectal cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Drug Ad | 2011 |
5-FU-induced cardiac toxicity--an underestimated problem in radiooncology?
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma; Cardiotoxins; Chemoradiotherapy; Electrocardiograp | 2012 |
A case of myocardial ischaemia induced by 5-fluorouracil.
Topics: Adenocarcinoma; Angina Pectoris; Antimetabolites, Antineoplastic; Colonic Neoplasms; Electrocardiogr | 2002 |
[Myocardial necrosis and cardiogenic shock with normal coronaries: cardiotoxicity due to 5-FU or catecholamine cardiomyopathy].
Topics: Antimetabolites, Antineoplastic; Cardiomyopathies; Catecholamines; Coronary Angiography; Coronary Ve | 2006 |
Severe ventricular dysrhythmias and silent ischemia during infusion of the antimetabolite 5-fluorouracil and cis-platin.
Topics: Adult; Antimetabolites, Antineoplastic; Arrhythmias, Cardiac; Cisplatin; Electrocardiography; Fluoro | 2006 |
[Myocardial ischaemia as a result of treatment with capecitabine].
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fl | 2007 |
[Myocardial ischaemia as a result of treatment with capecitabine].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Myocardial Ische | 2007 |
Myocardial ischemia induced by topical use of 5-fluorouracil.
Topics: Administration, Topical; Aged; Aged, 80 and over; Angina Pectoris; Carcinoma, Basal Cell; Drug Thera | 1995 |
The spectrum of 5-fluorouracil cardiotoxicity.
Topics: Adenoma; Aged; Carcinoma, Squamous Cell; Combined Modality Therapy; Digestive System Neoplasms; Fema | 1994 |
Myocardial ischemia after 5-fluorouracil chemotherapy.
Topics: Adult; Carcinoma; Fluorouracil; Humans; Male; Myocardial Ischemia; Tonsillar Neoplasms | 1993 |
In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle.
Topics: Animals; Antineoplastic Agents; Calcium Channels; Drug Interactions; Endothelium, Vascular; Fluorour | 1993 |
Failure of oral nitrate and calcium channel blocker therapy to prevent 5-fluorouracil-related myocardial ischemia: a case report.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Anus Neoplasms; Calcium Channel Blockers; Car | 1999 |
The use of raltitrexed (tomudex) in a patient with 5-fluorouracil induced myocardial ischaemia.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Enzyme Inhibitors; Female; Fluorouracil; Huma | 1999 |
Cardiotoxicity of 5-flourouracil: two case reports.
Topics: Angina Pectoris; Atrial Fibrillation; Female; Fluorouracil; Heart; Humans; Male; Middle Aged; Myocar | 2001 |
[Cardiotoxicity of 5-fluorouracil: ischemia or myocardial toxicity?].
Topics: Adult; Antimetabolites, Antineoplastic; Electrocardiography; Fluorouracil; Heart; Heart Diseases; Hu | 2001 |
[Cardiotoxicity of 5-fluorouracil. Clinical relevance of palliative radiochemotherapy of malignant head-neck tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Coronary Vasospasm; Fluor | 2001 |
Coronary vasospasm as a cause of effort-related myocardial ischemia during low-dose chronic continuous infusion of 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2001 |
[5-FU cardiotoxicity in adjuvant chemotherapy for colonic cancer letter)].
Topics: Chemotherapy, Adjuvant; Colonic Neoplasms; Female; Fluorouracil; Humans; Middle Aged; Myocardial Isc | 1992 |